RWML
DNLI icon

RAFFA WEALTH MANAGEMENT, LLC’s Denali Therapeutics DNLI Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26 Hold
1
– – ﹤0.01% 1562
2026
Q1 		$19 Buy
+1
New +$20 ﹤0.01% 1483
2021
Q2 		– Sell
-1
Closed -$57 – 1101
2021
Q1 		$57 Hold
1
– – ﹤0.01% 1098
2020
Q4 		$84 Buy
+1
New +$60 ﹤0.01% 909

Other funds holding DNLI

EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $833M AUM 22.71% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's DNLI Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 1 share worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in DNLI in Q4 2020 and has held it in 4 quarters since. The position peaked at $84 in Q4 2020. 46 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 1 share of Denali Therapeutics worth $26 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1562 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in Denali Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's Denali Therapeutics position peaked at $84 in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.